Related Experiment Video
Updated: Jul 17, 2026
13:02
Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis
Published on: November 4, 2017
8.6K
Fingolimod-associated Balo's concentric sclerosis in multiple sclerosis: A case report
Parisa Sharifi1, Amir Moradi2, Abdorreza Naser Moghadasi1
1Multiple Sclerosis Research Center, Neuroscience Institute Tehran University of Medical Sciences Tehran Iran.
Clinical Case Reports
|August 7, 2024
Summary
Fingolimod use in multiple sclerosis patients may be associated with Balo's concentric sclerosis. This case report highlights a potential adverse effect requiring further investigation in clinical practice.
Area of Science:
- Neurology
- Neuroimmunology
- Demyelinating Diseases
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Fingolimod is a sphingosine-1-phosphate receptor modulator used to treat relapsing forms of MS.
- Balo's concentric sclerosis (BCS) is a rare variant of MS characterized by concentric demyelination.
Observation:
- A patient with a prior diagnosis of multiple sclerosis was treated with fingolimod.
- The patient subsequently developed clinical and radiological evidence of Balo's concentric sclerosis.
Findings:
- This case report details the co-occurrence of Balo's concentric sclerosis and fingolimod treatment in a multiple sclerosis patient.
- The temporal relationship suggests a potential link between fingolimod and the development or exacerbation of BCS.
Implications:
- This finding warrants further investigation into the potential neurotoxic effects of fingolimod.
- Clinicians should be vigilant for BCS in multiple sclerosis patients undergoing fingolimod therapy.
- Understanding this association may inform treatment strategies and risk-benefit assessments for MS therapies.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...